¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Chronic persistent hepatitis, NEC"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
¿µ¹® acute hepatitis ÇÑ±Û ±Þ¼º°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼­ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, À̴ ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇϴ ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°À̸砳ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀ̠ã¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿­-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³­´Ù. µÚÀ̾î È²´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º­¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª È²´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â È²´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» Çصµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿­ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀ̠Ư¡À̸砱޼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º­¿î °ÍÀ̠Ư¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀΠ°ÍÀÌ º¸ÅëÀÌ´Ù.
¿µ¹® fulminant hepatitis ÇÑ±Û Àü°Ý°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º °£¿°ÀÇ ÇÑ ÇüÀ¸·Î ±Þ¼º È²»öÀ§ÃàÁõÀ̶ó°íµµ ºÎ¸¥´Ù. °£¼¼Æ÷ÀÇ ´ëºÎºÐÀÌ ±«»ç»óÅ·ΠµÇ¸ç È¯Àڴ º¸Åë »ç¸ÁÇÑ´Ù. È²´ÞÀÌ ³ªÅ¸³ª±â ÀüºÎÅÍ À̹̠Áõ»óÀº ÇöÀúÈ÷ ÁøÇàÇÏ¿© È²´ÞÀÇ ÃâÇöµµ ºü¸£°í, ±Þ¼º ¹ß¿­À» ¼ö¹ÝÇϸç Á¡¸·À̳ª ÇÇÇÏÃâÇ÷À» º¼ ¼ö ÀÖ´Ù. °£ÀÇ ¾ÐÅëÀ» ¼ö¹ÝÇϴ ¼öµµ ÀÖ´Ù. À§Ãà¿¡ ÀÇÇÏ¿© °£Àº ÀÚÁÖ ÀÛ¾ÆÁø´Ù. ÃÖÈÄ¿¡´Â ÀǽÄÀå¾Ö¸¦ ÃÊ·¡ÇÏ¿© Á¹À½ÀÌ ¿À°í È¥¹Ì»óÅ·ΠµÇ¸ç °£¼ºÈ¥¼ö·Î ÁøÇàÇÏ¿© »ç¸ÁÇϰԠµÈ´Ù. Áõ»óÀÌ ½ÃÀ۵Ǿî 2~3ÁÖ ³»¿¡ °£³úº´Áõ±îÁö ÁøÇàÇϴ °£±â´É »ó½ÇÀ» Àü°Ý¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸£¸ç, ÁøÇà ¼Óµµ°¡ ºü¸£Áö ¾Ê¾Æ¼­ 3°³¿ù¿¡ À̸£·¯ °£±â´É»ó½Ç¿¡ ºüÁö´Â °ÍÀº ¾Æ±Þ¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸¥´Ù. ¸ðµç °£¿° ¹ÙÀÌ·¯½º°¡ ¸ðµÎ ÀÏÀ¸Å°Áö´Â ¾Ê´Â´Ù. °£¿°A¹ÙÀÌ·¯½º¿Í °£¿°E¹ÙÀÌ·¯½º´Â º¸À¯ÀÚ »óųª ¸¸¼º °£¿°À» °ÅÀÇ ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. ±âŸ ´Ù¸¥ °¨¿° ¶Ç´Â ºñ°¨¿°¼º ¿øÀÎ, Æ¯È÷ ¾à¹°°ú µ¶¼Òµµ º»ÁúÀûÀ¸·Î µ¿ÀÏÇÑ ÁõÈĸ¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ±×·¯¹Ç·Î ¹ÙÀÌ·¯½º¼º °£¿°ÀÇ Áø´Ü°ú °¢ °£¿° ¹ÙÀÌ·¯½º¸¦ ±¸º°Çϴµ¥´Â Ç÷ûÇÐÀû °Ë»ç°¡ ÇʼöÀûÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • persistent vegetative state
    Áö¼Ó½Ä¹°»óÅÂ
  • persistent vomiting
    Áö¼Ó±¸Åä
  • anemia of chronic disease
    ¸¸¼ºº´ºóÇ÷
  • chronic
    ¸¸¼º-
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • chronic atrophic gastritis
    ¸¸¼ºÀ§ÃàÀ§¿°
  • chronic bronchitis
    ¸¸¼º±â°üÁö¿°
  • chronic exposure
    ¸¸¼º³ëÃâ
  • chronic fatigue syndrome
    ¸¸¼ºÇÇ·ÎÁõÈıº
  • chronic glomerulonephritis
    ¸¸¼ºÅ丮ÄáÆÏ¿°, ¸¸¼º»ç±¸Ã¼½Å¿°
  • chronic granulomatous disease
    ¸¸¼ºÀ°¾ÆÁ¾º´
  • chronic hypertrophic rhinitis
    ¸¸¼ººñÈÄÄÚ¿°, ¸¸¼ººñÈĺñ¿°
  • chronic lymphoblastic leukemia/small lymphocytic lymphoma
    ¸¸¼º¸²ÇÁ¸ð±¸¹éÇ÷º´/¼Ò¸²ÇÁ±¸¸²ÇÁÁ¾
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸¹éÇ÷º´
  • chronic myelocytic leukemia
    ¸¸¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • persistent hyaloid artery
    ÀÜ·ùÀ¯¸®Ã¼µ¿¸Æ
  • persistent cloaca
    ¹è¼³°­Á¸¼ÓÁõ
  • persistent acantholytic dermatosis
    Áö¼Ó°¡½Ã¼¼Æ÷ÇØ¸®ÇǺκ´
  • persistent superficial dermatitis
    Áö¼ÓÇ¥ÀçÇǺο°
  • persistent fetal hemoglobin
    Áö¼ÓžÆÇ÷»ö¼Ò
  • persistent infection
    Áö¼Ó°¨¿°
  • persistent o. primum ostium
    ù°±¸¸ÛÁö¼Ó(Áõ), ÀÏÂ÷°ø°³Á¸(Áõ)
  • persistent o. secundum ostium
    µÑ°±¸¸ÛÁö¼Ó(Áõ), ÀÌÂ÷°ø°³Á¸(Áõ)
  • persistent
    Áö¼Ó-, ÀÜ·ù-
  • persistent tremor
    Áö¼Ó¶³¸²
  • persistent vomiting
    Áö¼Ó±¸Åä
  • persistent cathode ray tube
    Áö¼ÓÀ½±Ø¼±°ü
  • persistent light reaction
    Áö¼Ó±¤¹ÝÀÀ
  • persistent palmoplantar pustulosis
    Áö¼Ó¼Õ¹ß¹Ù´Ú°í¸§¹°ÁýÁõ, Áö¼Ó¼Õ¹ß¹Ù´Ú³óÆ÷Áõ
  • persistent vegetative state
    Áö¼Ó½Ä¹°»óÅÂ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • persistent cloaca
    ¹è¼³°­Á¸¼ÓÁõ
  • persistent generalized lymphadenopathy
    Áö¼Ó¼º Àü½Å¼º ¸²ÇÁ¼±Áõ
  • persistent hyaloid artery
    À¯¸®Ã¼µ¿¸ÆÀÜ·ù
  • persistent hyperplastic vitreous
    ÀÏÂ÷À¯¸®Ã¼Áõ½ÄÁõ
  • persistent infection
    Áö¼Ó°¨¿°
  • persistent light reaction
    Áö¼Ó¼º ±¤¹ÝÀÀ
  • persistent ostium primum
    ÀÏÂ÷°ø°³Á¸(Áõ) (ìéó­ÍîËÒðíñø).
  • persistent ostium secundum
    ÀÌÂ÷°ø°³Á¸(Áõ)(ì£ó­ÍîËÒðíñø).
  • persistent pain
    Áö¼ÓÅë(ò¥áÙ÷Ô).
  • persistent palmoplantar pustulosis
    Áö¼Ó¼º ¼Õ¹ß¹Ù´Ú ³óÆ÷Áõ
  • persistent pupillary membrane
    µ¿°ø¸·Á¸¼Ó
  • persistent silent infection
    Áö¼Ó¼º Àẹ°¨¿°.
  • persistent somatoform pain disorder
    Áö¼Ó¼º ½ÅüÇü µ¿ÅëÀå¾Ö(º´)
  • persistent superficial dermatitis
    Áö¼Ó¼º Ç¥À缺 ÇǺο°
  • persistent tremor
    Áö¼Ó¼º ÁøÀü(ò¥áÙàõòèïµ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • persistent atrioventricular communis
    °øÅë ¹æ½Ç±¸(°ø)°³Á¸(Áõ)(Íì÷×Û®ãøÏ¢ÍîËÒðíñø).
  • persistent cathod ray tube
    Áö¼Ó¼º À½±Ø¼±°ü
  • persistent cloaca
    ¹è¼³°­Á¸¼ÓÁõ
  • persistent fetal circulation
  • persistent fetal hemoglobin
  • persistent generalized lymphadenopathy
    Áö¼Ó¼º Àü½Å¼º ¸²ÇÁ¼±Áõ
  • persistent hyaloid artery
    À¯¸®Ã¼µ¿¸ÆÀÜ·ù
  • persistent hyperlysinemia
  • persistent hyperplastic primary vitreous
  • persistent hyperplastic vitreous
    ÀÏÂ÷À¯¸®Ã¼Áõ½ÄÁõ
  • persistent infection
    Áö¼Ó°¨¿°
  • persistent light reaction
    Áö¼Ó¼º ±¤¹ÝÀÀ
  • persistent ostium primum
    ÀÏÂ÷°ø°³Á¸(Áõ) (ìéó­ÍîËÒðíñø).
  • persistent ostium secundum
    ÀÌÂ÷°ø°³Á¸(Áõ)(ì£ó­ÍîËÒðíñø).
  • persistent pain
    Áö¼ÓÅë(ò¥áÙ÷Ô).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CP candle power; capillary pressure; cardiac pacing; cardiac performance; cardiopulmonary; caudate puta...
CRD carbohydrate-recognition domain; chronic renal disease; chronic respiratory disease; child restraint...
NEC Necrotizing Entero-Colitis
If nec if necessary
NEC National Electrical Code; necrotizing enterocolitis; neuroendocrine cell; neuroendocrine convertase;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CAH Chronic Active Hepatitis
C.A.H. Chronic Aggressive Hepatitis
CH Chronic Hepatitis
cHC Chronic Hepatitis C
CLH Chronic Lobular Hepatitis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hepatitis B
    BÇü °£¿°
    BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ °£ÀÇ ¿°Áõ¼º ÁúȯÀ¸·Î¼­ Àü¼¼°èÀûÀ¸·Î À¯ÇàÇϸç À¯ÇàÀÌ °¡Àå ³ôÀº Áö¿ªÀº Áß°î°ú µ¿³²¾Æ, »çÇ϶ó ÁÖº¯ ¾ÆÇÁ¸®Ä«, ÅÂÆò¾ç±ºµµÀÇ ´ëºÎºÐ ¹× ¾Æ¸¶Á¸ À¯¿ª µîÀÌ´Ù.
  • hepatitis B virus
    BÇü °£¿° ¹ÙÀÌ·¯½º
    1. BÇü °¨¿° ȯÀÚ¿¡¼­ ¸ðµç ü¾× ³»·Î ¹æÃâµÇ´Â ¹ÙÀÌ·¯½º. 2. »ç¶÷ÀÇ °£¿¡ »ì¸ç, Ç÷û °£¿° µîÀ» ÀÏÀ¸Å°´Â ¹ÙÀÌ·¯½º. HB ¹ÙÀÌ·¯½º¶ó°íµµ ÇÑ´Ù. HBs Ç׿ø, HBc Ç׿ø, HBe Ç׿ø µî ¼¼ Á¾·ùÀÇ Ç׿ø ´Ü¹éÁúÀ» Áö´Ñ ¹ÙÀÌ·¯½ºÀÌ´Ù. ÀÌ °¡¿îµ¥ HBs Ç׿ø¿¡´Â º¹¼öÀÇ Ç׿ø °áÁ¤±â°¡ ÀÖ¾î, ±× ¦¸ÂÃã¿¡ µû¶ó BÇü °£¿° ¹ÙÀÌ·¯½º´Â adr, adw, ayr, aywÀÇ 4°¡Áö ¾ÆÇüÀ¸·Î ³ª´©¾îÁ® ÀÖ´Ù. 1965³â ¹Ì±¹ÀÇ S. ºí·³¹ö±×°¡ ¿À½ºÆ®·¹Àϸ®¾Æ ¿øÁÖ¹ÎÀÇ Ç÷û¿¡¼­ ¹ß°ßÇÏ¿© ´çÃÊ¿¡´Â Ç׿ø¼ºÀÌ ÀÖ´Â ¹°ÁúÀ̶ó°í º¸°í, HB Ç׿ø ¶Ç´Â ¿À½ºÆ®·¹Àϸ®¾Æ Ç׿øÀ̶ó°í ºÒ·¶´Ù. ±× ÈÄ DNA
  • infectious hepatitis virus
    Àü¿°¼º °£¿° ¹ÙÀÌ·¯½º
  • lupoid hepatitis
    ·çÇÁ½º¾ç °£¿°, À¯³¶Ã¢ °£¿°
    ¼Ò±¸Áø»ó º´º¯À» Ư¡À¸·Î ÇÏ´Â À¯À°Á¾ÁõÀÇ °£¿°.
  • neonatal hepatitis
    ½Å»ý¾Æ °£¿°
  • serum hepatitis
    Ç÷û °£¿°
    ¹ÙÀÌ·¯½º¼º °£¿° Áß BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÏ¿© °£ÀÌ Ä§ÇØµÇ´Â º´. Áõ¼¼´Â À¯Ç༺ °£¿°°ú º»ÁúÀûÀ¸·Î´Â ´Ù¸¦ ¹Ù°¡ ¾ø´Ù. ´Ù¼Ò ¿Ï¸¸ÇÏ°Ô ½ÃÀÛµÇÁö¸¸ °æ°ú°¡ ±æ°í, ¸¸¼ºÈ­ÀÇ °æÇâµµ °­ÇÏ´Ù. Àẹ±â´Â 60¡­90ÀÏÀε¥, ¼öÇ÷ ÈÄ 20ÀÏ Á¤µµ·Î ³ªÅ¸³ª´Â ¼öµµ ÀÖ´Ù. °¨¿° °æ·Î´Â Ç÷¾× ¹× Ç÷¾×Á¦Á¦
  • viral hepatitis
    ¹ÙÀÌ·¯½º °£¿°, ¹ÙÀÌ·¯½º¼º °£¿°
    ÃÖ¼Ò 5Á¾ÀÇ ¼­·Î ´Ù¸¥ ¹ÙÀÌ·¯½º°¡ ¿øÀÎÀÌ µÇ¸ç ÀÌµé ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î ÀÎÇÑ °£¿°.
  • chronic abscess
    ¸¸¼º ³ó¾ç
  • chronic acid
    Å©·Ò»ê
  • chronic acral dermatitis
    ¸¸¼º ¸»´Ü ÇǺο°
  • chronic actinic damage
    ¸¸¼º ±¤È­Çм± ¼Õ»ó
  • chronic alveolar abscess
    ¸¸¼º Ä¡Á¶ ³ó¾ç
    Ä¡±Ù´Ü Ä¡Á¶°ñÀÌ Àå±â°£ µ¿¾È ³·Àº Á¤µµ·Î °¨¿°µÈ °Í.
  • chronic ambulatory peritoneal dialysis
    Áö¼Ó¼º ¿Ü·¡ º¹¸· Åõ¼®
  • chronic atrophic candidiasis
    ¸¸¼º À§Ã༺ ĵµð´ÙÁõ
    º¸Ã¶¹°°ú Á¢Ã˵Ǵ ºÎÀ§ÀÇ Á¡¸·ÀÌ ¸Å²öÇϰí À§ÃàÀÌ µÇ¸ç ¸íÈ®ÇÏ°Ô Àû»öÀ¸·Î µÇ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÀÌÈÄ¿¡ À̰ÍÀº ±Ù¿øÀÌ ´Ù¸¥ º¸Ã¶¹° ±¸³»¿°°ú º¸Ã¶¹°¿¡ ´ëÇÑ Á¢Ã˼º ¾Ë·¹¸£±â ¹ÝÀÀ°ú ±¸ºÐÇÏ¿©¾ß ÇÏ´Â À¯µÎ¼º ¼Ò°ßÀ» À¯¹ßÇÒ °¡´É¼ºÀÌ ÀÖ´Ù.
  • chronic atrophic laryngitis
    ¸¸¼º À§Ãà Èĵο°, ¸¸¼º À§Ã༺ Èĵο°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
persistent ectopic pregnancy An ectopic pregnancy which has persistent viable tissue, secreting hCG after conservative surgery.
(05 Mar 2000)
persistent foetal circulation syndrome <syndrome> A syndrome of persistent pulmonary hypertension in the newborn infant, without demonstrable cardiac disease. It is characterised by cyanosis and acidosis, severe pulmonary vasoconstriction, hypertrophy of pulmonary arterial muscle, and elevated pulmonary vascular resistance, with resultant right-to-left shunting of blood through a patent ductus arteriosus and at times a patent foramen ovale.
(12 Dec 1998)
persistent generalised lymphadenopathy A syndrome characterised by reactive hyperplasia of lymph nodes (of at least one month's duration and at two different body sites, not including the inguinal area) in patients infected with the human immunodeficiency virus. The lymph node lesions progress from benign reactive hyperplasia through a stage of mixed follicular hyperplasia, to follicular involution with lymphocyte depletion. Many go on to a malignant non-Hodgkin's lymphoma.
(05 Mar 2000)
persistent mullerian duct syndrome <syndrome> Familial disorder with presence of fallopian tube, uterus, and testis in a male. Deficient mullerian inhibitory substance secondary to Sertoli cell defect.
Synonym: hernia uteri inguinale.
(05 Mar 2000)
persistent posterior hyperplastic primary vitreous A unilateral congenital anomaly in full-term infants; associated with a congenital retinal fold and a vitreous membranous stalk containing remnants of the hyaloid artery.
(05 Mar 2000)
persistent tremor A tremor that is constant, whether the subject is at rest or moving.
Synonym: continuous tremor.
(05 Mar 2000)
persistent truncus arteriosus A congenital cardiovascular deformity resulting from failure of development of the spiral septum and consisting of a common arterial trunk opening out of both ventricles, the pulmonary arteries being given off from the ascending common trunk.
(05 Mar 2000)
persistent vegetative state A persistent loss of upper cortical function that may follow acute (e.g., infections, toxins, trauma or vascular) events or chronic (e.g., degenerative) events. The patient is bedridden and nutritional support is completely passive, either parenteral or via nasogastric tube. The patient does not require respiratory support or circulatory assistance for survival and is in a state of chronic wakefulness without awareness which may be accompanied by spontaneous eye opening, grunts or screams, brief smiles, sporadic movement of facial muscles and limbs. While the eyes blink upon stimulation, they do not do so in response to visual threats. Some patients chew or clamp their teeth. Urinary and faecal incontinence is universal.
(12 Dec 1998)
truncus arteriosus, persistent A congenital anomaly resulting from the failure of the aorticopulmonary system to develop and divide the truncus arteriosus into the aorta and the pulmonary trunk.
(12 Dec 1998)
acute parenchymatous hepatitis A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice.
Synonym: acute parenchymatous hepatitis, Rokitansky's disease.
(05 Mar 2000)
anicteric hepatitis Hepatitis without jaundice.
(05 Mar 2000)
anicteric virus hepatitis A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis.
(05 Mar 2000)
autoimmune hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
vaccination, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
vaccination, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á